792.        Vlassara H, et al. “Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.” Proceedings of the National Academy of Science of the United States of America, Volume 99, Number 24, Pages 15596–15601. November 26, 2002. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=137762

793.        Lyons TJ, et al. “Decrease in Skin Collagen Glycation with Improved Glycemic Control in Patients with Insulin-dependent Diabetes Mellitus.” Journal of Clinical Investigation, Volume 87, Number 6, Pages 1910–1915. June 1991. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=296942

794.        Takamiya R, et al. “Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis.” FASEB Journal, Express Article, 10.1096/fj.02-0768fje. http://www.fasebj.org/cgi/content/abstract/02-0768fjev1

795.        Münch G, et al. “Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation.” Journal of Chemical Neuroanatomy, Volume 20, Issues 3-4, Pages 253-257. December 2000, http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T02-42C07TD-6&_user=10&_coverDate=12%2F31%2F2000&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=79c1965fdbd0c91e20bbb4f8aa1537ac

796.        Kalousova M, et al. “Advanced Glycoxidation End Products in Patients with Multiple Sclerosis.”  Prague Medical Report, Volumeume 106, Number 2, Pages 167–174. 2005. http://www.galenicom.com/pt/medline/article/16315765

797.        Bhawal UK, et al. “Association of Expression of Receptor for Advanced Glycation End Products and Invasive Activity of Oral Squamous Cell Carcinoma.” Oncology. Volume 69, Pages 246-255. 2005. http://content.karger.com/ProdukteDB/produkte.asp?Doi=87910

798.        Thornalley PJ. “Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.” Biochemical Society Transactions. Volume 31, Part 6. 2003. http://www.biochemsoctrans.org/bst/031/1372/0311372.pdf

799.        Klimek A. “ISLET AMYLOID - A CULPRIT IN TYPE 2 DIABETES.” The Science Creative Quarterly.  Issue Two. September-November 2006.. http://www.scq.ubc.ca/islet-amyloid-a-culprit-in-type-2-diabetes

800.        Chou SM, et al.. “Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis.” Molecular Medicine. Volume 4, Number 5, Pages 324-32. May 1998. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=9642682&dopt=Citation

801.        Ahmad N, et al. “Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes.” Diabetes Care. Volume 28, Number 10. Pages 2465-2471, 2005. http://care.diabetesjournals.org/cgi/reprint/28/10/2465

802.        Genuth S, et al. “Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes.” Diabetes. Volume 54, Number 11, Pages 3103–3111, November 2005. http://diabetes.diabetesjournals.org/cgi/content/full/54/11/3103?ck=nck

803.        Bartling B, et al. “Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma.” Carcinogenesis. Volume.26, Number 2, Pages 293--301, 2005. http://carcin.oxfordjournals.org/cgi/reprint/26/2/293

804.        Kuniyasu H, et al. “Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer.” ONCOLOGY REPORTS. Volume 10, Pages 445-448, 2003. http://histology1.med.uoc.gror/2003/Volume10/number2/445.pdf

805.        Jeroen WJ, et al. “Advanced Glycation End Products in Human Cancer Tissues: Detection of N-(Carboxymethyl)lysine and Argpyrimidine.” Annals of New York Academy of. Science. Volume 1043, Number 1, Pages 725–733. 2005. http://www.annalsnyas.org/cgi/content/abstract/1043/1/725

806.        Harata K, et al. “Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells.” Hepatogastroenterology. Volume 50, Number 53, Pages 1205-7. September-October 2003. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14571699&dopt=Abstract

807.        Dickerson TJ and Janda KD. “A previously undescribed chemical link between smoking and metabolic disease.” Proceedings of the National Academy of Science of the United States of America,. Volume 99, Number 23, Pages 15084–15088.  November 12, 2002. http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137547

808.        Monnier VM, et al. “Accelerated age-related browning of human collagen in diabetes mellitus.” Proceedings of the National Academy of Science of the United States of America, Volume 81, Number 2, Pages 583–587. January 1984. http://www.pubmedcentral.gov/articlerender.fcgi?artid=344723

809.        Dyer DG, et al. “Accumulation of Maillard reaction products in skin collagen in diabetes and aging.” Journal of Clinical Investigation, Volume 91, Number 6, Pages 2463–2469. June 1993. http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=443306

810.        Stader RH, et al. “Acrylamide from Maillard reaction products.” Nature. Volume 419, Number 6906, Pages 449-50. October 3, 2002. http://www.nature.com/nature/journal/v419/n6906/abs/419449a.html;jsessionid=EC52C7B8BF019CC01F201A782AD6CE17

811.        Lu M, et al. “Advanced glycation end products increase retinal vascular endothelial growth factor expression.” Journal of Clinical Investigation, Volume 101, Number 6, Pages 1219–1224. March 15, 1998. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=508675&blobtype=pdf

812.        Newkirk MM, et al. “Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis.” Arthritis Research Therapies, Volume 5, Number 2, Pages R82–R90. 2003. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=165032

813.        Kalousováa, M, et al. “Advanced glycoxidation end products in chronic diseases—clinical chemistry and genetic background.” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. Volume 579, Issues 1-2, Pages 37-46, November 11, 2005. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T2C-4GT7V6X-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=f9294eddf1cef29f6e6fb8cd8b66d765

814.        Smith MA, et al. “Advanced Maillard reaction end products are associated with Alzheimer disease pathology.” Proceedings of the National Academy of Science of the United States of America, Volume 91, Number 12, Pages 5710–5714. June 7, 1994. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44066

815.        Yan SD, et al. “Amyloid-b peptide–Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease.” Proceedings of the National Academy of Science of the United States of America, Volume 94, Pages 5296–5301, May 1997. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=24672&blobtype=pdf

816.        Wolffenbuttel BHR, et al. “Breakers of advanced glycation end products restore large artery properties in experimental diabetes.” Proceedings of the National Academy of Science of the United States of America, Volume 95, Issue 8, Pages 4630-4634, April 14, 1998. http://www.pnas.org/cgi/reprint/95/8/4630

817.        Huebschmann AG, et al. “Diabetes and Advanced Glycoxidation End Products.” Diabetes Care. Volume 29, Number 6, Pages 1420-1432. June 2006. http://care.diabetesjournals.org/cgi/reprint/29/6/1420.pdf

818.        Wu L, ET AL. “Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system.” Proceedings of the National Academy of Science of the United States of America, Volume 101, Number18, Pages 7094–7099. May 4, 2004. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=406471&blobtype=pdf

819.        Misciagna G, et al. “Dietary Carbohydrates and Glycated Proteins in the Blood in Non Diabetic Subjects.” Journal of the American College of Nutrition, Volume 24, Number 1, Pages 22-29. 2005. http://www.jacn.org/cgi/content/abstract/24/1/22

820.        Chang C-J et al. “Effects of Glucose and –Tocopherol on Low-Density Lipoprotein Oxidation and Glycation.” Annals of the.New York Academy of Science.  Volume 1042, Pages 294–302. May 2005. http://www.annalsnyas.org/cgi/content/abstract/1042/1/294

821.        Ahmed N and Furth AJ. “Failure of common glycation assays to detect glycation by fructose.” Clinical Chemistry. Volume 38, Number 7, Pages 1301-3. July 1992. http://www.clinchem.org/cgi/reprint/38/7/1301

822.        McPherson JD, et al. “Role of fructose in glycation and cross-linking of proteins.” Biochemistry. Volume 27, Number 6, Pages 1901-7. March 22, 1988. http://www.ncbi.nlm.nih.gov/sites/entrez

823.        Lehman TD, et al. “Inhibitors of advanced glycation end product-associated protein cross-linking.” Biochimica et Biophysica Acta. Volume 1535, Number 2, Pages 110-9. Feb 14, 2001. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1Y-428143F3&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=a4c613f418bad13673798f20e12d3b4a

824.        Khaw K-T, et al. “Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk).” British Medical Journal.  Volume 322, Number 7277, Page 15. January 6, 2001. http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26599

825.        Legendary Pharmaceuticals. “Background: Glycation and Crosslinking Proteins.” http://www.legendarypharma.com/glycation.html

826.        Obrenovich ME and Monnier VM. “Glycation stimulates amyloid formation.” Science of Aging Knowledge Environment. Volume 2004, Number 2, pe3. January 14, 2004. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14724325&dopt=Abstract

827.        Veiraiah A. “Hyperglycemia, lipoprotein glycation, and vascular disease.” Angiology. 2005 Jul-Aug Volume 56, Number 4, Pages 431-8. July-August 2005. http://www.ncbi.nlm.nih.gov/entrez/eutils/escan.fcgi?db=PubMed&uid=16079928&dopt=Citation&field=Title&DateField=MeshDate

828.        Lamharzi N, et al. “Hyperlipidemia in Concert With Hyperglycemia Stimulates the Proliferation of Macrophages in Atherosclerotic Lesions. Potential Role of Glucose-Oxidized LDL.” Diabetes.  Volume 53, Pages 3217-3225. 2004. http://diabetes.diabetesjournals.org/cgi/reprint/53/12/3217

829.        Zhang J, et al. “Influence of Glycation on LDL-Induced Generation of Fibrinolytic Regulators in Vascular Endothelial Cells.”  Arteriosclerosis, Thrombosis, and Vascular Biology. Volume18, Pages 140-1148. 1998. http://atvb.ahajournals.org/cgi/reprint/18/7/1140

830.        Bierhaus A, et al. “Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.” Journal of Clinical Investigation, Volume 114, Number 12, Pages 1741–1751. December 15, 2004. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=535062&blobtype=pdf

831.        Takamiya R, et al. “Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis.” FASEB Journal. Express Article 10.1096/fj.02-0768fje. Published online March 5, 2003. http://www.fasebj.org/cgi/content/abstract/02-0768fjev1

832.        Bucala R, et al. “Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.” Proceedings of the National Academy of Science of the United States of America, Volume 9, Number 20, Pages 9441–9445. September 27, 1994. http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=44828

833.        Acosta J, et al. “Molecular basis for a link between complement and the vascular complications of diabetes” Proceedings of the National Academy of Science of the United States of America,. Volume 97, Number 10, Pages 5450–5455. May 9, 2000. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=25849&blobtype=pdf

834.        Kieseier, BC and Hartung, H-P. “Multiple paradigm shifts in multiple sclerosis. Demyelinating diseases.” Current Opinion in Neurology.  Volume 16, Number 3, Pages 247-252. June 2003.  http://www.co-neurology.com/pt/re/coneuro/abstract.00019052-200306000-00001.htm;jsessionid=HVbCyt0kYpvDGXy1wJYjC9ZjzvHskSh2ttJR1919HLpfvqTq42hM!1717287316!181195628!8091!-1

835.        Columbia University Health Science. “Multiple Sclerosis: Reducing RAGE. Blocking the RAGE Receptoer prevents multiple sclerosis symptoms in mice.” IN VOVO. Volume 2, Number 5. March 12, 2003. http://www.cumc.columbia.edu/news/in-vivo/Vol2_Iss05_mar12_03/index.html

836.        Garlick RL, et al. “Nonenzymatic glycation of human lens crystallin. Effect of aging and diabetes mellitus.” Journal of Clinical Investigation, 1984 November Volume 74, Number 5, Pages 1742–1749.  November 1984. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=425353&blobtype=pdf

837.        Shibata N, et al. “Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation.” Acta Neuropathologica. Volume 100, Number 3, Pages 275-284. July 2000. http://www.springerlink.com/content/ukpr2mvqyrn36pw3/

838.        Ahmed N, et al. “Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.” Journal of Neurochemistry. Volume 92, Number 2, Pages 255–263. January 2005. http://www.blackwell-synergy.com/doi/abs/10.1111/j.1471-4159.2004.02864.x

839.        Hou FF, et al. “Receptor for Advanced Glycation End Products on Human Synovial Fibroblasts: Role in the Pathogenesis of Dialysis-Related Amyloidosis.” Journal of the American Society of Nephrology. Volume 13, Pages 1296-1306. 2002. http://jasn.asnjournals.org/cgi/reprint/13/5/1296

840.        Wauther JL and Guillausseau PJ. “ADVANCED GLYCATION END PRODUCTS, THEIR RECEPTORS AND DIABETIC ANGIOPATHY.” Diabetes and Metabolism. (Paris) 2001 Volume 27, Pages 535-542. 2001. http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&uid=11694852&cmd=showdetailview&indexed=google

841.        Holm E. et al. “Structural studies of a carbohydrate-containing immunoglobulin-lambda-light-chain amyloid-fibril protein (AL) of variable subgroup III.” Biochemical Journal. Volume 239, Number 3, Pages 545–551. November 1, 1986. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1147321

842.        Kaufmanna, E, et al. “The advanced glycation end-product N -(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.” Neuroscience Letters. Volume 371, Issues 2-3, Pages 226-229. November 23, 2004. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T0G-4DDRB2C-3&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=6087df0af06bda5f8e4b52774a5dca88

843.        Lachin JM, et al. “The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial.” Diabetes.. Volume 56(, Number 7, Pages 1161-1772. 2007. http://www.medscape.com/viewarticle/560882_print

844.        Cerami C, et al. “Tobacco smoke is a source of toxic reactive glycation products.” Proceedings of the National Academy of Science of the United States of America, Volume 94, Number 25, Pages 13915–13920. December 9, 1997. http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=28407&blobtype=pdf

845.        Anderson MM, et al. “The myeloperoxidase system of human phagocytes generates Ne-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation.” Journal of  Clinical Investigation. Volume 104, Number 1, Pages 103–113. July 1, 1999. http://www.pubmedcentral.gov/articlerender.fcgi?artid=408396

846.        Sasaki N, et al. “Advanced Glycation End Products in Alzheimer’s Disease and Other Neurodegenerative Diseases.” American Journal of Pathology. Volume 153, Pages 1149–1155. 1998. http://ajp.amjpathol.org/cgi/reprint/153/4/1149.pdf

847.        Bouma B, et al. “Glycation Induces Formation of Amyloid Cross- Structure in Albumin.” Journal of Biological Chemistry. Volume 278, Issue 43,, Pages 41810-41819, October 24, 2003. http://www.jbc.org/cgi/reprint/278/43/41810

848.        Kikuchi S, et al. “Glycation—a sweet tempter for neuronal death.” Brain Research Reviews. Volume 41, Pages 306–323. 2003. http://www.alteon.com/scientific_publications/role/Br_Res_Rev_41_306_03.pdf

849.        Tamarat R, et al. “Blockade of advanced glycation end-product formation restores ischemia- induced angiogenesis in diabetic mice.” Proceedings of the National Academy of Science of the United States of America. Volume 100, Number 14, Pages 8555–8560.. July 8, 2003. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=166267